@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo

President Donald Trump sits at his desk, behind a hat that reads "America is back" at the White House in Washington, Feb. 3, 2026. Evelyn Hockstein | Reuters President Donald Trump on Tuesday said "the federal government should get involved" in elections in states that are unable to "legally and honestly" administer them on their own. If they can't, then "somebody else should take over," Trump said in the Oval Office after he signed a bill to fund the federal government. The comments show Trump is not backing off his recent suggestion that Republicans should "nationalize" elections, even as Democrats raise concerns that the administration may try to interfere in the upcoming midterms. "If a state can't run an election, I think the people behind me should do something about it," Trump said in the Oval Office, referring to the handful of Republican lawmakers standing around him. He had been asked what he meant when, in a podcast interview released Monday, he called on members of the Republican Party to "take over the voting." "The Republicans should say, 'We want to take over. We should take over the voting, the voting in at least many — 15 places ... the Republicans ought to nationalize the voting,'" Trump said in that interview with former deputy FBI director Dan Bongino. Read more CNBC politics coverage Trump: If states can't run elections 'honestly,' then 'somebody else should take over' Trump signs bill ending federal government shutdown Sen. Warner calls Gabbard to testify over GA election raid, Trump call Trump: Powell probe over Fed HQ renovation should continue Trump pardon attorney Ed Martin reportedly sidelined from investigations How global dark fleet of tankers is navigating high seas hunt for sanctioned oil House hardliners complicate ending government shutdown as Speaker Johnson moves ahead Trump says U.S. and India reached trade deal, will lower tariffs immediately Trump spoke at the White House hours after the House narrowly approved a measure to end ...

格隆汇2月4日｜Wind数据显示，周三（2月4日），共有7家公司限售股解禁，合计解禁量为1654.97万股，按最新收盘价计算，合计解禁市值为1.84亿元。从解禁量来看，中设咨询、格林美、吉冈精密解禁量居前，解禁股数分别为960.29万股、246.57万股、174.35万股。从解禁市值来看，中设咨询、国源科技、吉冈精密解禁市值居前，解禁市值分别为7816.74万元、3170.12万元、2404.27万元。从解禁股数占总股本比例来看，中设咨询、国源科技、吉冈精密解禁比例居前，解禁比例分别为6.26%、1.23%、0.65%。

中信建投（601066）指出，ChatGPT首批广告将在2026年2月初上线，仅面向免费及Go订阅层用户，初期按CPM(展示次数)收费。中信建投（601066）认为OpenAI广告变现较克制，且回答不给予广告权重，较好平衡了用户体验；异于移动互联网时代，大模型边际成本不会随用户增长而降低，算力等成本反而随用户增长、对话量增加而增长，挖掘免费用户商业价值是打通商业闭环的必经之路，广告等多元变现方式是To C属性较强的大模型公司的必选。

来源：华尔街情报圈 ——把“最拥挤的交易”先踢出去。 又是一个令人惊诧的交易日： - 黄金 和 白银 强势反弹，金价接近5000美元，银价接近90美元； - 美国股市全线 下跌 ，道琼斯指数跌0.34%，标普500指数跌0.84%，纳斯达克指数跌1.43%； - 比特币大跌，至特朗普当选总统以来的最低点； - 美元和美债收益率小幅 下跌 。 表面上看，这是一个普通的交易日，但实际上这是一个“风险转移”的交易日。 第一，黄金和白银的强势反弹，掩盖了 下跌 的声音——美股与比特币同步 下跌 ，才是“真正的主线”——这是一场被世界忽略的 下跌 。 - 虽然美股指数还好，但真正的重灾区是软件股，软件板块一天近4%（像被人一刀切断）——这是过去美股交易中最为拥挤的部分。这与前几天黄金暴跌是一样的情形，不是一次普通的 下跌 ，而是一场“挤在同一扇门口的人，同时想出去”的事故。不是观点变化，是仓位结构出问题。 - 比特币大跌，不是因为它本身出了什么事，而是它被当成了风险偏好最纯粹的表达（提前报警）。所以它总是先跌、跌得更狠。 如果这是一次具有传导性质的 下跌 ，那么还会传导至其他“拥挤交易”。 第二，黄金、白银在涨，但涨势“并不张扬”——金价在5000美元附近犹豫，银价在90美元附近出现回吐——如果这是趋势性行情，它们不会走得这么犹豫。更像前期快速 下跌 后的技术修复，而非确认开启一轮涨势（是在“恢复体力”，而不是“起跑”）。黄金收盘站上5140美元（最好连续两个交易日）才能算是重新上涨的开始。 第三，美元和美债“没怎么动”。美元和美债的克制，说明市场还在“减仓”，而不是“下结论”。市场还在观望，这是一次可控的去风险，还是需要更激进防御的阶段？这更像2018、而不是2008或2020。 这是一个不断试探你的风险承受力的市场，而不是一次性击倒你的市场。

Image source: The Motley Fool. Tuesday, Feb. 3, 2026 at 5:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Peter Konieczny Chief Financial Officer — Steve Scherger TAKEAWAYS Total Revenue -- $5.4 billion for the quarter, driven by the Berry acquisition. -- $5.4 billion for the quarter, driven by the Berry acquisition. Adjusted EPS -- $0.86 per share reported, reflecting a 7% increase for the quarter and a 14% increase for the first half. -- $0.86 per share reported, reflecting a 7% increase for the quarter and a 14% increase for the first half. Comparable Adjusted EBIT -- Up 7%, with synergy benefits fully offsetting lower volumes. -- Up 7%, with synergy benefits fully offsetting lower volumes. Synergy Realization -- $55 million of benefits in Q2 and $93 million for the first half, at the upper end of guidance. -- $55 million of benefits in Q2 and $93 million for the first half, at the upper end of guidance. Core Portfolio Volumes -- Down approximately 1.5%, outperforming the total portfolio by 100 basis points. -- Down approximately 1.5%, outperforming the total portfolio by 100 basis points. Adjusted EPS Full-Year Guidance -- Reaffirmed at $4.20 to $4.50 per share, reflecting recent reverse split. -- Reaffirmed at $4.20 to $4.50 per share, reflecting recent reverse split. Synergy Guidance Fiscal 2026 -- On track to deliver at least $260 million this fiscal year, with a total target of $650 million by fiscal 2028. -- On track to deliver at least $260 million this fiscal year, with a total target of $650 million by fiscal 2028. Free Cash Flow -- Reported at $289 million for the quarter after $70 million of acquisition-related costs. -- Reported at $289 million for the quarter after $70 million of acquisition-related costs. Quarterly Dividend -- 65¢ per share declared, higher than the prior year. -- 65¢ per share declared, higher than the prior year. Non-Core Portfolio Optimization -- $2.5 billion of non-core businesses under review, including the North America...

Dmitry Vinogradov/iStock Editorial via Getty Images In today's column, we check back in on the just-reported performance of Advanced Micro Devices, Inc. ( AMD ), in its fourth-quarter results . Our ongoing opinion has been that the premium shares enjoy could only be unjustified if the performance came in less than expected. While there are anxieties about AI-related spending ongoing indefinitely, competition issues, an OpenAI ( OPENAI ) partnership, and the broader market, in our opinion the results are strong. Let us discuss the quarter. Based on the expectations and the outlook, we do not see shares as expensive. They are at a premium, but the growth results and expectations suggest the valuation will continue to grow. Any breather in shares is an investing opportunity in our estimation. AMD is a world-class operation and just put out a top-and-bottom-line beat in its Q4, and it solidifies the assertion that chips, which used to be so very cyclical, are secular given the AI demand. Will AI-related spending be reduced in the future? Possibly, but there are no signs that the time is now. In late 2024, we gave an outlook on AMD and its Q4 report . We will not go into heavy detail repeating the expectations, but a few major items are notable to reiterate. We were expecting $9.75 billion in revenue, plus or minus $200 million. At the midpoint of the revenue range, this represents year-over-year growth of nearly 30% and sequential growth of about 5.4%. We expected adjusted margins to approach 55%, up from Q3. We expected data center demand to be higher, client segment strength, and a gaming segment rebound. We will also say that our early expectation for 2026 was margins of 53%-55% and operating margins of 25%, with $6.50-$7.00 in EPS for the year 2026. These results suggest these expectations for 2026 are reasonable, especially considering the Q1 guide. The overall Q4 earnings were strong. The headline revenues and earnings easily surpassed consensus. The numbers were ...

Dmitry Vinogradov/iStock Editorial via Getty Images In today's column, we check back in on the just-reported performance of Advanced Micro Devices, Inc. ( AMD ), in its fourth-quarter results . Our ongoing opinion has been that the premium shares enjoy could only be unjustified if the performance came in less than expected. While there are anxieties about AI-related spending ongoing indefinitely, competition issues, an OpenAI ( OPENAI ) partnership, and the broader market, in our opinion the results are strong. Let us discuss the quarter. Based on the expectations and the outlook, we do not see shares as expensive. They are at a premium, but the growth results and expectations suggest the valuation will continue to grow. Any breather in shares is an investing opportunity in our estimation. AMD is a world-class operation and just put out a top-and-bottom-line beat in its Q4, and it solidifies the assertion that chips, which used to be so very cyclical, are secular given the AI demand. Will AI-related spending be reduced in the future? Possibly, but there are no signs that the time is now. In late 2024, we gave an outlook on AMD and its Q4 report . We will not go into heavy detail repeating the expectations, but a few major items are notable to reiterate. We were expecting $9.75 billion in revenue, plus or minus $200 million. At the midpoint of the revenue range, this represents year-over-year growth of nearly 30% and sequential growth of about 5.4%. We expected adjusted margins to approach 55%, up from Q3. We expected data center demand to be higher, client segment strength, and a gaming segment rebound. We will also say that our early expectation for 2026 was margins of 53%-55% and operating margins of 25%, with $6.50-$7.00 in EPS for the year 2026. These results suggest these expectations for 2026 are reasonable, especially considering the Q1 guide. The overall Q4 earnings were strong. The headline revenues and earnings easily surpassed consensus. The numbers were ...

Nuke-Sniffing Helicopter Spotted Over San Francisco Ahead Of Super Bowl A U.S. Department of Energy helicopter operating under the callsign "ENERGY14," used for aerial radiological detection, was spotted in the San Francisco metro area ahead of the Super Bowl this weekend. The nuclear-sniffing helicopter, which flies with specialized sensor pods that detect gamma and neutron radiation and map radioactive plumes in real time, was observed surveying over parts of the San Francisco metro area on Monday. Open-source intelligence accounts documented ENERGY14's flight path using Flightradar24 data. X user TheIntelFrog noted that the helicopter was "conducting low-level sweeps over the San Francisco area to obtain baseline samples before Super Bowl LX." National Nuclear Security Administration N2314 as ENRGY14 conducting low level sweeps over the San Francisco area to obtain baseline samples before Super Bowl LX. pic.twitter.com/Czr1dDPhIy — TheIntelFrog (@TheIntelFrog) February 2, 2026 Another X user documented ENERGY14's radiological aerial survey of the metro area. San Francisco getting it's first Nuke scan before the Super Bowl pic.twitter.com/4CQ9IoZHTR — Joe (@0xosprey) February 2, 2026 SF Jet Spotter snapped photos of the helicopter. “ENERGY14” Nuke-Sniffing Helicopter Surveilling San Francisco ahead of this weekends Super Bowl pic.twitter.com/sEgBA9k2Ml — SF Jet Spotter (@SFJET147) February 2, 2026 Beyond the nuke-sniffing mission, we wonder what type of layered counter-UAS threat detection is in place around Levi's Stadium in Santa Clara, California, given the event's high profile. Tyler Durden Tue, 02/03/2026 - 18:50

Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments. Expand NYSE : NVO Novo Nordisk Today's Change ( -14.75 %) $ -8.69 Current Price $ 50.24 Key Data Points Market Cap $199B Day's Range $ 49.96 - $ 58.63 52wk Range $ 43.08 - $ 93.80 Volume 3.7M Avg Vol 21M Gross Margin 81.93 % Dividend Yield 2.93 % Novo Nordisk (NVO 14.75%), a diabetes and obesity drug maker, closed Tuesday at $50.33, down 14.59%. The stock sold off after management projected a 2026 sales and profit decline despite strong recent results, and investors are watching how it defends U.S. obesity-drug share and pricing. The company’s trading volume reached 67.7 million shares, which is about 218% above its three-month average of 21.3 million shares. Novo Nordisk went public in 1981 and has grown more than 3,1000% since its IPO. How the markets moved today S&P 500 (SNPINDEX: ^GSPC) slipped 0.85% to 6,917, while the Nasdaq Composite (NASDAQINDEX: ^IXIC) fell 1.43% to 23,255 as growth stocks lost ground. Among pharmaceuticals peers, Eli Lilly (LLY 3.90%) closed at $1,002.98, down 3.94%, while Novartis (NVS 0.78%) finished at $149.86, off 0.78%, reflecting broader pressure across large drugmakers. What this means for investors Novo Nordisk shares fell sharply on Tuesday after management projected a decline in sales and profit in 2026, prompting investors to reset expectations despite strong recent performance. The sell-off was driven by concerns over U.S. pricing pressure and intensifying competition in the obesity-drug market. Management forecast a 5%–13% drop in 2026 sales, citing price cuts, patent expirations, and a more crowded competitive landscape, particularly in the U.S., where Novo Nordisk has built much of its recent momentum. The company’s management has outlined an expanded obesity strategy and leadership changes in the U.S. business, alongside continued development of next-gen...

Representative Raja Krishnamoorthi (D) Illinois discusses what reforms & changes Democrats want to see with ICE that will help Congress reach a compromise on DHS funding. He also voices his reaction to President Trump’s “Project Vault,” and its importance to compete with China. Rep. Krishnamoorthi speaks with Joe Mathieu and Julie Fine on the late edition of Bloomberg’s “Balance of Power.” (Source: Bloomberg)

人工智能领域的一次常规更新引发了法律软件板块的剧烈震荡。 Anthropic上周五为其Claude Cowork AI代理推出的法律插件，在周二触发了相关股票的集体暴跌，多只个股跌幅超过15%。 这家Claude AI聊天机器人的开发商推出的 新工具能够执行多项文书工作，包括追踪合规事项和审阅法律文档。这些功能正是许多法律软件产品的核心所在。 摩根士丹利分析师 Toni Kaplan等人 在一份关于汤森路透的报告中写道： Anthropic为其Claude Cowork AI代理在法律领域推出了新功能，加剧了该领域的竞争。我们认为这是竞争加剧的迹象，因此可能带来负面影响。 周二第一波抛售潮主要集中在与法律和数据服务技术相关的股票上，随后大部分软件板块和金融科技板块也纷纷跟跌。 由于市场对商业发展公司和华尔街大型另类投资公司的股票普遍持有软件业务的担忧加剧，这些公司的股票也遭受重创。 当日软件、金融服务和资产管理行业的股票市值总共蒸发了约 2850 亿美元。 荷兰威科集团重挫13%，英国励讯集团下跌14%，LegalZoom.com暴跌近20%，汤森路透下跌15%。 （LegalZoom.com暴跌近20%） 这些股票在2026年迄今均已累计下跌至少20%，年初的渐进式下滑在Anthropic法律插件发布后急剧加速。分析认为，尽管AI颠覆威胁已被纳入华尔街对2026年的展望，但投资者对AI代理带来的冲击仍保持高度警惕。 Claude在专业领域的市场地位 在竞争激烈的AI市场中，Claude已成为众多法律和金融专业人士进行分析工作的首选工具。 Anthropic在其插件网站上提供的法律工具，声称可以自动完成合同审查和法律简报等工作。该网站还指出：“所有输出结果均应由持证律师审核。” Anthropic构建的模型可以根据行业的具体需求进行定制。作为人工智能生态系统中的主要模型开发商，Anthropic拥有独特的优势，能够颠覆传统的法律新闻和数据服务，以及法律人工智能领域的新兴企业。 据Business Insider报道，知名做空者Andrew Left去年表示，他在为即将到来的诉讼案件进行研究时使用了该工具。 传统法律信息巨头遭冲击 周二受影响的股票中，仅LegalZoom专门从事法律行业业务，通过提供指南和独立律师服务帮助客户简化任务。 英国IT集团RELX通过旗下法...

传统制冷剂淡季，制冷剂行情维持稳中偏强运行。据百川盈孚市场监测，2026年1月以来，第三代主流制冷剂R32均价稳定在6.3万元/吨，同比增长约45%；R134a市场均价稳定在5.8万元/吨，同比增长32%；截至2月3日，R125、R410a分别同比增长16%和29%，并且这两种制冷剂自2025年四季度以来均出现持续上涨趋势。申万宏源认为，2026年各企业HFCs配额已下发，在全球供给严格约束下，行业格局优化叠加下游需求的增长，将带来制冷剂价格和价差的长周期向上，制冷剂作为功能性制剂，“刚需消费品”属性与“特需经营”商业模式的“基因”正在逐步形成。有行业研究员对记者表示，目前企业生产以执行长协订单为主，不过市场价格会高于长协价格。总体看，行业主流报价维持在较高水平，主流制冷剂价格均高于去年同期。以R32为例，2025年一季度，其价格为4.3万元/吨至4.7万元/吨。今年1月以来，R32均价稳定在6.3万元/吨。可以预测，在行业高景气度的加持下，今年一季度制冷剂龙头企业的业绩依然不俗。（上海证券报）

自2024年红果跻身行业第一至今，短剧行业格局已经很长时间趋于稳定。 断层式领先的红果，几乎集行业所有高光于一身，爱奇艺、优酷、腾讯视频、B站、百度、小红书等其他玩家，鲜少诞生破圈的爆款短剧，业务规模也常常比较隐秘。 进入2026年，拥有14.14亿月活跃用户的微信，似乎成了短剧行业的一个新变量。1月中旬的微信公开课上，腾讯主动对外披露了一些数据，外界得以窥见微信短剧增长态势。 腾讯官方数据显示，2025年，微信生态短剧主体增长超31%，收入破千万的公司超90家，真人短剧数量近30万部，漫剧上架增长达惊人的3380%，成为增长最快的细分赛道。此外，2025年视频号上线原生短剧后，一个季度的时间，日流水从0突破千万级，多部短剧收益突破百万，播放量破亿。 虽然与红果相比，微信生态短剧体量还很小。但它的想象空间在于，拥有互联网第一用户规模的微信，如果按照抖音流量灌溉的方式发力短剧，很容易复制出另一个红果，它的业务上限会很高。 微信生态短剧未来能否颠覆行业格局，暂时先打个问号。眼下，微信短剧生态是否完善，谁在微信短剧生态掘金？除了90多家收入破千万，其他玩家真实收益如何？ 微信短剧大多为老剧，版方收入几十万元 腾讯对短剧越来越重视。 腾讯董事会主席兼首席执行官马化腾已经连续两年提到短剧。2026年1月26日的腾讯年会上，马化腾再度谈及短剧。他表示，腾讯视频在2025年“没有那么多爆款产品”，需给予一定耐心，这与投入周期相关。腾讯视频去年受到短剧的冲击，后续除了坚持高品质长视频投入，也要做一些广告驱动型产品。 在此之前，2025年初，马化腾首次公开谈及短剧，承认“短剧对长内容造成较大的冲击”，并表示坚持精品短剧战略方向，加大对短剧的投入。 腾讯布局短剧业务比较分散，腾讯视频、微信小程序、视频号几个平台多线并进。微信生态短剧主要是小程序短剧与视频号短剧，二者目前皆没有独立的入口。从小程序入口进入页面，“短剧”位于发现小程序下部比较靠前的推荐位置，优于影视与音乐、教育教学、餐饮美食类目。“短剧”页面内，微信短剧小程序推出了包括“口碑榜”“漫剧榜”“总榜”“新剧榜”“热搜榜”在内的多个短剧榜单。 具体来看，微信小程序短剧大多为老剧。短剧总榜显示，排在第一名的是《裴总每天都想父凭子贵》，该剧为短剧厂牌听花岛2024年1月份上线的作品。排名二三的短剧《归来风云》《邂逅孕佳人》也都是此前...

来源：环球市场播报 当地时间周二，法国巴黎检方表示，已对美国企业家马斯克旗下社交媒体平台X在巴黎的办公场所展开搜查。 据悉，此次行动属于巴黎检察院网络犯罪打击部门于2025年1月 立案 调查的一部分，调查由法国国家宪兵网络犯罪部门负责实施，并有欧洲刑警组织在场配合。 与此同时，法国司法部门已向X平台负责人发出传唤通知。根据检方通报，X平台实际负责人埃隆·马斯克被要求于2026年4月20日在巴黎接受“自由听证”，就相关指控作出说明。此外，多名X平台员工也被传唤，将于2026年4月20日至24日期间以证人身份接受质询。 马斯克在X上回应用户对这一事件的评论时称：“这是一次政治攻击。” 马斯克还转发了自己的粉丝“DogeDesigner”的一条帖子，后者表示“法国应当调查马克龙与爱泼斯坦之间的关系，而非突击搜查X的办公室。” 他在回应另一位网友的帖子时表示，法国的司法部门“实际上并非独立的。”

ORCL Stock Heads to $120 as Massive $50 Billion AI Cost Clouds Oracle’s Valuation FXLeaders

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo

1月4日，，在德国新乌尔姆举办的乒乓球德国杯决赛中，樊振东所在的萨尔布吕肯队夺得冠军。 （新华社） 中国乒协公示伦敦世乒赛团体赛选拔办法，奥运冠军樊振东符合标准。 中国乒乓球协会星期二（2月3日）在官网正式公示《2026年国际乒联伦敦世界乒乓球团体锦标赛决赛选拔办法》，明确了本届世乒赛团体赛的参赛运动员选拔标准、公示要求及报名截止时间等关键信息。 据紫牛新闻报道，根据选拔办法的第1、2条，2025年国际乒联多哈世界乒乓球锦标赛决赛男子单打冠军王楚钦、十五运乒乓球项目成年组男子单打冠军樊振东，2025年国际乒联多哈世界乒乓球锦标赛决赛女子单打冠军孙颖莎，十五运乒乓球项目成年组女子单打冠军王曼昱，均直接获得参赛资格。 根据选拔办法的第3条，以2月9日国际乒联公布的单打世界排名为标准，单打排名最高的两名国乒队男子运动员直接入选。以最新一期国际乒联公布的单打世界排名作为参考，男子单打，中国队球员王楚钦、林诗栋位列前二，女子单打，中国队球员孙颖莎、王曼昱占据前二。若2月9日排名无重大变动，上述四名运动员可直接入选。 本次选拔办法公示期为2026年2月3日至6日，运动员、教练员建议名单完成内部报批后，将在中国乒协官网公布后正式向国际乒联提交。 2026年国际乒联伦敦世界乒乓球团体锦标赛决赛将于4月28日至5月10日在英国伦敦举办，恰逢世乒赛百年庆典，目前已经完成各支球队的抽签分组。

This pre-revenue biopharmaceutical stock is a home run swing worth taking. Obesity is a global health crisis and is a direct or indirect cause of various health conditions. The emergence of GLP-1 agonists over the past several years has ignited one of the most significant market opportunities in the modern history of healthcare. Research from Morgan Stanley estimates that the global obesity drug market could reach $150 billion by 2035, up from $15 billion in 2024. Novo Nordisk and Eli Lilly are the heavyweights that control the industry right now, but don't sleep on Viking Therapeutics (VKTX 1.89%). This $3.3 billion stock still has much to prove, but buying it now while it trades around $30 a share could make investors look like geniuses later. Some investors may avoid Viking Therapeutics because the company doesn't generate any sales yet It's still developing its first drugs, headlined by VK2735, a dual GLP-1 and GIP agonist drug similar to Eli Lilly's Zepbound. Viking Therapeutics is developing both a subcutaneous (injected) version and an oral (pill) version. The subcutaneous version is in phase 3 trials, with an estimated completion date of August 2027. The oral pill, which recently completed a phase 2a study, is further behind. The bad news? Viking Therapeutics may not bring a product to market, assuming regulatory approval, until at least 2028. The good news? Novo Nordisk and Eli Lilly are validating the long-term market opportunity. Both have enjoyed strong growth from their subcutaneous products, and Novo Nordisk recently launched the first oral GLP-1 agonist, which looks like a home run. While VK2735 may be a ways off, clinical trials have signaled it could be very competitive. Expand NASDAQ : VKTX Viking Therapeutics Today's Change ( -1.89 %) $ -0.56 Current Price $ 29.36 Key Data Points Market Cap $3.4B Day's Range $ 28.57 - $ 30.69 52wk Range $ 18.92 - $ 43.15 Volume 76K Avg Vol 3.2M A $3.5 billion market valuation means high risk, high potential reward...

Federal Reserve Board Governor Stephen Miran speaks on "Regulations, the Supply Side, and Monetary Policy" during the Delphi Economic Forum Lecture event, at the National Gallery in Athens, Greece, January 14, 2026. Louisa Gouliamaki | Reuters Federal Reserve Governor Stephen Miran has stepped down from his position as chair of the Council of Economic Advisers, CNBC confirmed. Miran joined the Council of Economic Advisers in January 2025. He became a member of the Federal Reserve Board of Governors in September 2025, filling a term that ended on Jan. 31. This is breaking news. Please refresh for updates.

Source: Bloomberg, 5:50

格隆汇2月4日｜一位美国官员表示，伊朗革命卫队原计划于上周日和本周一在霍尔木兹海峡进行实弹军事演习，但在收到美国的警告后取消了演习。

sasacvetkovic33/E+ via Getty Images Kolibri Global Energy ( KGEI ) is in a position of growth in a challenging oil environment, pushing for improved yields at its Oklahoma shale locations. With improving cost efficiencies and scaled operating efficiencies, KEI has maintained a relatively strong adjusted EBITDA margin in recent years with the expectation of maintaining a roughly 75% margin for eFY25. Despite the challenging oil market, KGEI shares are fundamentally undervalued at 4.08x EV/aEBITDA. Using a fundamental approach, I believe KGEI shares should be priced at $4.29/share at 3.83x eFY26 EV/aEBITDA; I am recommending shares with a "Buy" rating. Kolibri Global Energy Operations KEI has grown by a substantial rate in recent years, with average production expanding by 40% to 4,254 boe/d in Q3’25. Higher production has created improved operating leverage for the firm in recent years, with the average operating cost per barrel coming down to $6.57/boe [net of production tax adjustment] in Q3’25, down from $6.63/boe in Q3’24. Corporate Filings Looking to eQ4’25, KEI may be in a challenging position regarding the price per barrel continuing its decline, potentially adding some pressure to bringing new barrels into production. Corporate Filings Despite the challenging oil environment, KEI utilizes a comprehensive hedge book, which may offset some of the pricing headwinds expected in eQ4’25. Corporate Filings As of January 2026, KEI had 53.6 MMboe in 2P reserves, 78% of which were proved, undeveloped reserves [PUD], with the remaining being proved, developed, and producing [PDP]. Corporate Filings In January 2026 , KEI reported improving performance in the Tishomingo Shale Oil Field in Oklahoma, potentially hinting at a production uplift for eQ4’25 on the back of relatively flat oil prices. Accordingly, the new producing wells in the region should also improve KEI’s production mix for eq4’25 with the expectation of oil being 75% of total production in November 2025, up...

瑞銀位於西九龍高鐵總站上蓋、新地發展的IGC的香港總部「瑞銀中心」正式交接。 新大樓總樓面面積45萬平方呎，樓高14層。 瑞銀表示，將於今年第四季開始正式啟用，分階段將集團在本港不同辦公室工作的同事陸續轉移到新大樓，預料年底前完成搬遷。 管理層形容，西九是本港的新一頁，大樓可直達高鐵西九龍總站、機場快線及西九文化區，將加強集團與大灣區及環球市場的聯繫，鞏固香港作為全球金融樞紐的地位。強調集團非常重視本港市場，未來會繼續投放資源，重點發展財富管理領域，對本港及大灣區發展充滿信心。 瑞銀財富管理亞洲區主席盧彩雲︰「大灣區，大家都知道有十一個城市、8,700萬人口、2萬億元的國內生產總值、有50萬高淨值的客戶。現時香港新股市場都非常活躍，還有400家正排隊上市，所以我們在投資銀行方面的活動都非常活躍。香港房地產我們都是審慎樂觀，我們可以租成幢大廈，我們對未來香港市場發展都是有信心和看好。」